Strattice Mesh Lawsuit Scheduled for First Federal Bellwether Trial

Strattice Mesh Lawsuit Scheduled For First Federal Bellwether Trial

Lawyers involved in Strattice hernia mesh lawsuits filed in the U.S. District Court for the District of New Jersey will meet with the federal judge presiding over the litigation tomorrow, to discuss preparations for the first of at least two early test trials, which the Court has indicated should be ready to begin by February 2026.

The Strattice Reconstructive Tissue Matrix is a hernia repair mesh that was introduced in 2008, and is constructed from porcine, or pig skin, which is then preserved in a phosphate buffered aqueous solution. It is marketed as a cross-linked graft device, intended to chemically link the proteins in the tissue together.

In recent years, the Strattice manufacturer has faced dozens of hernia mesh lawsuits alleging that the design actually increases the risk of foreign body responses, infections and other complications. Many of the complaints suggest that the hernia mesh products were defectively designed, with the U.S. Food and Drug Administration (FDA) receiving 450 medical device reports involving the Strattice from 1990 through 2020, including at least six deaths, 340 injuries and 107 mesh malfunctions.

Is there a hernia mesh lawsuit? Find out if you qualify for a hernia mesh lawsuit settlement payout.
Is there a hernia mesh lawsuit? Find out if you qualify for a hernia mesh lawsuit settlement payout.

While most claims have been filed in New Jersey state court, and have been consolidated into a Strattice multicounty litigation (MCL), lawsuits have also been filed in federal court in the District of New Jersey, where the manufacturer, Lifecell Corporation, is headquartered.

Late last month, U.S. Magistrate Judge Leda D. Wettre issued an amended case management order (PDF), indicating that the first bellwether trial will involve a claim by Robert Sandoval, which is expected to go before a jury in February 2026. The trials are designed to test how juries will respond to evidence and testimony likely to be repeated throughout the litigation, in hopes of setting the stage for a Strattice hernia mesh lawsuit settlement agreement.

The order outlines a timeline of key deadlines leading up to trial, starting with a status conference this Wednesday. Opening briefs for dispositive and related expert motions are due by August 5, with responses due by September 5, and replies by September 15. Separate expert motion briefs must be filed by September 25, followed by responses due October 17 and replies by October 28.

No date has yet been set for the second trial, but there will be at least a four month gap between the two trials.

While the results of those bellwether trials will not be binding on other claims, if no Strattice settlement agreement results from the test cases, the lawsuits will likely be remanded for individual trial dates.

Sign up for more legal news that could affect your or your family.


Written By: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

A neurosurgeon and a personal injury lawyer weigh in on new evidence linking Depo-Provera to brain tumors, as lawsuits mount against Pfizer over failure to warn about meningioma risks.